Relapsing Remitting Multiple Sclerosis (RRMS)iPROACT-MSNCT07318129
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
A study testing Indole-3-propionic acid (IPA) in people with Relapsing Remitting Multiple Sclerosis (RRMS), run by Glostrup University Hospital, Copenhagen at 1 site in Denmark.
Trial summary
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Relapsing Remitting Multiple Sclerosis (RRMS)
- What is being tested?
- Indole-3-propionic acid (IPA)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 220 participants
- Where
- 1 siteDenmark
- Study dates
- 26 Jan 2026to 15 Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Women and men ≥18 and ≤65 years of age
- Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates)
- Routinely treated and monitored for MS
- Speak and read Danish
- Deemed physically and mentally able to participate in this study
Who cannot join
- Active malignancy
- Diagnosis of Crohn's disease and ulcerative colitis
- Other comorbidities deemed to be relevant
- Haematopoietic stem cell transplantation
- Current or past treatment with non-MS related treatments deemed to be relevant
- Pregnancy or lactation
Show all 9Show fewer
- People with MR contraindications:
- Severe claustrophobia
- Incompatible implants/ foreign objects, including implanted pacemakers, heart valve prostheses, prostheses in the middle ear, implanted devices (e.g., insulin pump), metal debris, e.g., metal splinters in the eyes, miscellaneous shunts and catheters, metal clips from operations
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Jette Lautrup Frederiksen, MD, dr.med, professor contact
Denmark1 site, 1 recruiting
- Recruiting
Glostrup Hospital
Glostrup Municipality, 2600
Jette Lautrup Frederiksen, MD, dr.med, professor, +45386330, jette.lautrup.battistini@regionh.dk
About this study
Official title: Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis (iPROACT-MS)
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
- Being tested
- Placebo, Indole-3-propionic acid (IPA)
- Keywords
- indole-3-propionic acid, multiple sclerosis, gut bacterial metabolite, dietary supplement, gut-brain axis
- Medical subject headings
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDietary supplement
Two capsules are taken every morning and two capsules are taken every evening for 27 consecutive months. Placebo capsules are taken orally.
Indole-3-propionic acid (IPA)Dietary supplement
Two capsules are taken every morning and two capsules are taken every evening for 27 consecutive months. Active capsules are taken orally and contain 250 mg of IPA each resulting in a total daily dose of 1000 mg of IPA.
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Placebo capsules Receives: Dietary Supplement: Placebo |
| Indole-3-propionic acid (IPA) | Experimental | IPA capsules Receives: Dietary Supplement: Indole-3-propionic acid (IPA) |
What is being measured
The primary outcome is the main question the study is designed to answer.
No evidence of disease activity (NEDA)
The percentage of patients that maintain no evidence of disease activity (NEDA-3) in the time between month 3 and month 27 after initiation of supplementation. NEDA-3 is defined as a binary composite consisting of absence of confirmed relapses, no new or enlarged lesions on brain MRI and no confirmed disability progression. For relapses to be confirmed, they need to be accompanied by an increase of at least 0.5 points on the EDSS or 2 points in one of the EDSS functional system scores, or at least 1 point in two or more of the EDSS functional system scores. Confirmed disability progression is defined as an increase in the EDSS score compared to EDSS at month 3 which is of at least 1 point (or 0.5 points if the baseline EDSS >5.5) and is sustained for three months (measured at month 12 and confirmed at month 15 or measured at month 24 and confirmed at month 27 or measured at a relapse evaluation prior to or at month 24 and confirmed at the next visit or the latest at month 27).
Measured: The time between month 3 and month 27 after initiation of supplementation.
Secondary outcomes (25)
Annualized relapse rate evaluated at month 27
Defined as the total number of confirmed relapses experienced during the intervention for each patient divided by years of exposure to the intervention and excluding the first three months for both outcome and exposure.
Measured: The time between month 3 and month 27 after initiation of supplementation.
Total (cumulative) number of new or enlarged T2-weighted/FLAIR brain lesions per scheduled yearly MRI evaluated at month 27
New or enlarged brain lesions are evaluated at month 15 and compared to month 3 and at month 27 and compared to month 15; results from unscheduled MRIs between month 3 and month 27 are also considered.
Measured: The time between month 3 and month 27 after initiation of supplementation.
Serum neurofilament light chain (sNfL)
Measured: Evaluated longitudinally at months 0, 3, 15 and 27.
Percentage of patients with disability improvement confirmed at 3 months
Confirmed disability improvement is defined as a reduction in EDSS (expanded disability status scale) score compared to EDSS at month 3 which is of at least 1 point (or 0.5 points if the baseline EDSS >5.5). The EDSS score ranges from 0 to 10 with 0 indicating no neurological disability and 10 indicating death from MS. Measured at month 12 and confirmed at month 15 or measured at month 24 and confirmed at month 27.
Measured: The time between month 3 and month 27 after initiation of supplementation.
The time to onset of disability worsening confirmed at 3 months
Confirmed disability worsening is defined as an increase in the EDSS (expanded disability status scale) score compared to EDSS at month 3 which is of at least 1 point (or 0.5 points if the baseline EDSS >5.5). The EDSS score ranges from 0 to 10 with 0 indicating no neurological disability and 10 indicating death from MS. Measured at month 12 and confirmed at month 15 or measured at month 24 and confirmed at month 27 or measured at a relapse evaluation prior to or at month 24 and confirmed at the next visit or the latest at month 27.
Measured: The time between month 3 and month 27 after initiation of supplementation.
Cumulative change in EDSS score
Calculated as area under the curve (AUC) for measured values of the EDSS (expanded disability status scale) score from month 3 to month 24. The EDSS score ranges from 0 to 10 with 0 indicating no neurological disability and 10 indicating death from MS.
Measured: The time between month 3 and month 24 after initiation of supplementation.
Multiple Sclerosis Functional Composite (MSFC)
A composite score used to assess neurological function by combining results from the Timed 25-Foot Walk (T25FW) test, the Nine-Hole Peg Test (9HPT) and the Symbol Digit Modalities Test (SDMT) evaluated at months 0, 12 and 24.
Measured: The time between month 0 and month 24 after initiation of supplementation.
Symbol Digit Modalities Test (SDMT)
A measure of cognitive function and especially processing speed - evaluated at months 0, 12 and 24.
Measured: The time between month 0 and month 24 after initiation of supplementation.
California Verbal Learning Test-II (CVLT-II)
A measure of verbal learning and memory - evaluated at months 0, 12 and 24.
Measured: The time between month 0 and month 24 after initiation of supplementation.
Brief Visuospatial Memory Test - Revised (BVMR-R)
A measure of visuospatial memory - evaluated at months 0, 12 and 24.
Measured: The time between month 0 and month 24 after initiation of supplementation.
Intra-eye change in peripapillary retinal nerve fiber layer (RNFL) thickness
Measured using Optical Coherence Tomography (OCT) at months 0, 12 and 24.
Measured: The time between month 0 and month 24 after initiation of supplementation.
Intra-eye change in ganglion cell and inner plexiform layer (GCIPL) thickness
Measured using Optical Coherence Tomography (OCT) at months 0, 12 and 24.
Measured: The time between month 0 and month 24 after initiation of supplementation.
Modified Fatigue Impact Scale (MFIS-21)
The MFIS-21 consists of a physical subscale (ranges from 0-36), a cognitive subscale (ranges from 0-40) and a psychosocial subscale (ranges from 0-8). The total MFIS-21 scale is computed by adding the scores from the physical, the cognitive and the psychosocial subscales. It ranges from 0-84 with higher scores indicating a greater impact from fatigue. MFIS-21 is evaluated longitudinally at months 0, 3, 6, 9, 12, 15, 18, 21, 24 and 27.
Measured: The time between month 0 and month 24 after initiation of supplementation.
Multiple Sclerosis Quality of Life-54 (MSQOL-54)
The MSQOL-54 questionnaire is used to calculate a physical health composite score and a mental health composite score. They both range from 0-100 with higher scores indicating better health/ higher quality of life. The questionnaire is administered at months 0, 12 and 24.
Measured: The time between month 0 and month 24 after initiation of supplementation.
Brain-derived neurotrophic factor (BDNF)
Brain-derived neurotrophic factor measured in platelet-free plasma samples using ELISA or mesoscale. Monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
C-reactive protein (CRP)
CRP measured in plasma (mg/L) as a biomarker of infection and systemic inflammation. Lower-limit of quantification: 0,4 mg/L. Values below 0,4 mg/L are imputed as 0,2 mg/L. Monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
Triglycerides
Plasma triglycerides (mmol/l) monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
Non-HDL cholesterol
Non-HDL cholesterol calculated as total cholesterol minus HDL cholesterol (mmol/l). Monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
C-peptide
Proinsulin C-peptide (pmol/l) measured in plasma. Monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
Fasting glucose
Plasma glucose (mmol/l). Participants abstain from eating and drinking after 22.00 the day before. Only water is allowed. Monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
8-iso-prostaglandin F2α and other F2-isoprostanes
F2-isoprostanes with a specific focus on 8-iso-prostaglandin F2α measured in morningurine or blood samples as a marker of oxidative stress-related lipid oxidation. Monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
8-oxo-dG
8-oxo-dG (8-Oxo-2'-deoxyguanosine) measured in blood or morningurine samples as a marker of oxidative stress-related DNA damage. Monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
Fecal lipocalin
Lipocalin measured in fecal samples as a sensitive biomarker of intestinal inflammation. Monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
Microbiota profiling of fecal samples
Microbiota profiling of fecal samples using molecular biology methods including but not limited to sequencing and flowcytometric analyses. Monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
Serum and fecal metabolomics
Targetted and untargetted liquid-chromatography mass-spectrometry-based metabolomics to measure diet-, host- and microbial-derived metabolites. Targetted analyses aim to quantify indole-3-propionic acid and its metabolites (biomarker of compliance as well as absorptive and metabolic capacity), other bacterial- and host metabolites of tryptophan as well as short-chain fatty acids. Monitored longitudinally at months 0, 3, 15 and 27.
Measured: The time between month 0 and month 27 after initiation of supplementation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2026
- Study start26 Jan 2026
- Primary completion15 Jul 2028 (estimated)
- Study completion15 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Relapsing Remitting Multiple Sclerosis (RRMS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 220 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Glostrup University Hospital, Copenhagen
- Sponsor type
- University, hospital or other
- Collaborators
- University of Copenhagen, University of Southampton
- Responsible party
- Principal investigator, Jette Lautrup Frederiksen, Glostrup University Hospital, Copenhagen
- Investigators
- Jette Lautrup Frederiksen, MD, dr.med, professor, Principal investigator, Copenhagen University Hospital, Rigshospitalet-Glostrup
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07318129
- Sponsor's protocol ID
- H-25042489
- Acronym
- iPROACT-MS
- Status last verified
- Dec 2025
- First submitted
- 23 Nov 2025
- Last updated
- 28 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data that underlie the results reported in published articles, after deidentification (text, tables, figures, and appendices).
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis (iPROACT-MS)
- ClinicalTrials.gov ID
- NCT07318129
- Acronym / sponsor ID
- iPROACT-MS / H-25042489
- Keywords
- indole-3-propionic acid, multiple sclerosis, gut bacterial metabolite, dietary supplement, gut-brain axis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 220 participants (estimated)
- Lead sponsor
- Glostrup University Hospital, CopenhagenUniversity, hospital or other
- Collaborators
- University of Copenhagen, University of Southampton
- Study start
- 26 Jan 2026 (actual)
- Primary completion
- 15 Jul 2028 (estimated)
- Study completion
- 15 Jul 2028 (estimated)
- First posted
- 5 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Dietary Supplement: PlaceboPlacebo capsules |
| Indole-3-propionic acid (IPA) | Experimental | Dietary Supplement: Indole-3-propionic acid (IPA)IPA capsules |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Women and men ≥18 and ≤65 years of age
- Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates)
- Routinely treated and monitored for MS
- Speak and read Danish
- Deemed physically and mentally able to participate in this study
Key exclusion criteria (9 listed)
- Active malignancy
- Diagnosis of Crohn's disease and ulcerative colitis
- Other comorbidities deemed to be relevant
- Haematopoietic stem cell transplantation
- Current or past treatment with non-MS related treatments deemed to be relevant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboTwo capsules are taken every morning and two capsules are taken every evening for 27 consecutive months. Placebo capsules are taken orally. | Dietary supplement | Placebo |
| Indole-3-propionic acid (IPA)Two capsules are taken every morning and two capsules are taken every evening for 27 consecutive months. Active capsules are taken orally and contain 250 mg of IPA each resulting in a total daily dose of 1000 mg of IPA. | Dietary supplement | Indole-3-propionic acid (IPA) |
Primary outcome
No evidence of disease activity (NEDA)
Time frame: The time between month 3 and month 27 after initiation of supplementation.
The percentage of patients that maintain no evidence of disease activity (NEDA-3) in the time between month 3 and month 27 after initiation of supplementation. NEDA-3 is defined as a binary composite consisting of absence of confirmed relapses, no new or enlarged lesions on brain MRI and no confirmed disability progression. For relapses to be confirmed, they need to be accompanied by an increase of at least 0.5 points on the EDSS or 2 points in one of the EDSS functional system scores, or at least 1 point in two or more of the EDSS functional system scores. Confirmed disability progression is defined as an increase in the EDSS score compared to EDSS at month 3 which is of at least 1 point (or 0.5 points if the baseline EDSS >5.5) and is sustained for three months (measured at month 12 and confirmed at month 15 or measured at month 24 and confirmed at month 27 or measured at a relapse evaluation prior to or at month 24 and confirmed at the next visit or the latest at month 27).
25 secondary outcomes
Annualized relapse rate evaluated at month 27
Time frame: The time between month 3 and month 27 after initiation of supplementation.
Total (cumulative) number of new or enlarged T2-weighted/FLAIR brain lesions per scheduled yearly MRI evaluated at month 27
Time frame: The time between month 3 and month 27 after initiation of supplementation.
Serum neurofilament light chain (sNfL)
Time frame: Evaluated longitudinally at months 0, 3, 15 and 27.
Percentage of patients with disability improvement confirmed at 3 months
Time frame: The time between month 3 and month 27 after initiation of supplementation.
The time to onset of disability worsening confirmed at 3 months
Time frame: The time between month 3 and month 27 after initiation of supplementation.
Cumulative change in EDSS score
Time frame: The time between month 3 and month 24 after initiation of supplementation.
Multiple Sclerosis Functional Composite (MSFC)
Time frame: The time between month 0 and month 24 after initiation of supplementation.
Symbol Digit Modalities Test (SDMT)
Time frame: The time between month 0 and month 24 after initiation of supplementation.
California Verbal Learning Test-II (CVLT-II)
Time frame: The time between month 0 and month 24 after initiation of supplementation.
Brief Visuospatial Memory Test - Revised (BVMR-R)
Time frame: The time between month 0 and month 24 after initiation of supplementation.
Intra-eye change in peripapillary retinal nerve fiber layer (RNFL) thickness
Time frame: The time between month 0 and month 24 after initiation of supplementation.
Intra-eye change in ganglion cell and inner plexiform layer (GCIPL) thickness
Time frame: The time between month 0 and month 24 after initiation of supplementation.
Modified Fatigue Impact Scale (MFIS-21)
Time frame: The time between month 0 and month 24 after initiation of supplementation.
Multiple Sclerosis Quality of Life-54 (MSQOL-54)
Time frame: The time between month 0 and month 24 after initiation of supplementation.
Brain-derived neurotrophic factor (BDNF)
Time frame: The time between month 0 and month 27 after initiation of supplementation.
C-reactive protein (CRP)
Time frame: The time between month 0 and month 27 after initiation of supplementation.
Triglycerides
Time frame: The time between month 0 and month 27 after initiation of supplementation.
Non-HDL cholesterol
Time frame: The time between month 0 and month 27 after initiation of supplementation.
C-peptide
Time frame: The time between month 0 and month 27 after initiation of supplementation.
Fasting glucose
Time frame: The time between month 0 and month 27 after initiation of supplementation.
8-iso-prostaglandin F2α and other F2-isoprostanes
Time frame: The time between month 0 and month 27 after initiation of supplementation.
8-oxo-dG
Time frame: The time between month 0 and month 27 after initiation of supplementation.
Fecal lipocalin
Time frame: The time between month 0 and month 27 after initiation of supplementation.
Microbiota profiling of fecal samples
Time frame: The time between month 0 and month 27 after initiation of supplementation.
Serum and fecal metabolomics
Time frame: The time between month 0 and month 27 after initiation of supplementation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2026.
- Individual participant dataSharing planned: Yes. Individual participant data that underlie the results reported in published articles, after deidentification (text, tables, figures, and appendices).
Related trials for Relapsing Remitting Multiple Sclerosis (RRMS)
Not yet recruitingPhase 2
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Relapsing-remitting Multiple Sclerosis
Active, not recruitingPhase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Relapsing-remitting Multiple Sclerosis (RRMS)
Active, not recruitingPhase 4
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
Multiple Sclerosis, Relapsing-Remitting
RecruitingPhase 2
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
Relapsing-remitting Multiple Sclerosis (RRMS)
Active, not recruitingPhase 3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Relapsing-remitting Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jette Lautrup Frederiksen, MD, dr.med, professor contact
Jette Lautrup Frederiksen, MD, dr.med, professor principal investigator
Copenhagen University Hospital, Rigshospitalet-Glostrup
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Indole-3-propionic acid (IPA) in people with Relapsing Remitting Multiple Sclerosis (RRMS), run by Glostrup University Hospital, Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jette Lautrup Frederiksen, MD, dr.med, professor (+4538633041, jette.lautrup.battistini@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
No evidence of disease activity (NEDA) (time frame: The time between month 3 and month 27 after initiation of supplementation.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2026.